Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Gains from Investment Securities: 2011-2024

Historic Gains from Investment Securities for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to $17.6 million.

  • Ptc Therapeutics' Gains from Investment Securities fell 101.50% to -$100,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $43.9 million, marking a year-over-year increase of 335.05%. This contributed to the annual value of $17.6 million for FY2024, which is 113.74% up from last year.
  • Ptc Therapeutics' Gains from Investment Securities amounted to $17.6 million in FY2024, which was up 113.74% from -$127.7 million recorded in FY2023.
  • Ptc Therapeutics' Gains from Investment Securities' 5-year high stood at $76.8 million during FY2020, with a 5-year trough of -$127.7 million in FY2023.
  • Over the past 3 years, Ptc Therapeutics' median Gains from Investment Securities value was $17.6 million (recorded in 2024), while the average stood at -$24.8 million.
  • As far as peak fluctuations go, Ptc Therapeutics' Gains from Investment Securities skyrocketed by 364.67% in 2022, and later crashed by 456.53% in 2023.
  • Yearly analysis of 5 years shows Ptc Therapeutics' Gains from Investment Securities stood at $76.8 million in 2020, then plummeted by 89.96% to $7.7 million in 2021, then surged by 364.67% to $35.8 million in 2022, then tumbled by 456.53% to -$127.7 million in 2023, then soared by 113.74% to $17.6 million in 2024.